Semglee and Lantus contain the same active ingredient, insulin glargine, at the same concentration of 100 units per mL. They are not identical products, but Semglee is so close to Lantus that the FDA designated it as the first-ever interchangeable biosimilar in 2021, meaning pharmacists can substitute one for the other without needing to contact your prescriber.
What “Interchangeable Biosimilar” Means for You
Biologics like insulin are made from living cells, so a copy can never be a perfect molecular clone the way a generic pill can replicate a brand-name tablet. Instead, the FDA created the “biosimilar” category for products that are highly similar to an existing biologic with no clinically meaningful differences. Semglee cleared that bar and then went a step further: it received an interchangeability designation, which carries a higher standard of evidence.
In practical terms, interchangeability means your pharmacist can fill a Lantus prescription with Semglee (and vice versa) without calling your doctor first, just like they would with a generic drug. State pharmacy laws govern exactly how this works, and most states allow the switch automatically, though your pharmacist may notify your prescriber after the fact. If you pick up your prescription and see “insulin glargine-yfgn” on the label instead of Lantus, that’s Semglee.
How the Two Compare Clinically
The FDA approval rested on two Phase 3 clinical trials, one in people with type 1 diabetes and one in type 2 diabetes. Both were randomized, head-to-head comparisons against Lantus over 24 weeks, measuring changes in HbA1c (the standard marker of long-term blood sugar control). Semglee met the bar for non-inferiority in both trials, meaning it lowered blood sugar just as effectively as Lantus.
The safety profile is also comparable. Both products carry the same risks: hypoglycemia is the most common side effect, and the same precautions about injection site reactions and allergic reactions apply. If you’ve been stable on Lantus, you can expect the same level of blood sugar control on Semglee.
Small Differences in Formulation
The active ingredient and its concentration are identical. The inactive ingredients are nearly the same, with one minor difference: the Semglee vial formulation includes a tiny amount of polysorbate-20 (20 micrograms per mL) as a stabilizer, which the prefilled pen version does not contain. Both formulations use the same preservative (metacresol), the same buffer system, and the same zinc content. These small variations are typical of biosimilars and do not affect how the insulin works in your body.
Switching From Lantus to Semglee
If you’re currently on Lantus (100 units/mL), the switch to Semglee is straightforward: you use the same dose, the same injection schedule, and the same injection technique. No dose adjustment is needed when moving between two insulin glargine 100 unit/mL products.
Dose adjustments are only necessary when switching from a different type of insulin altogether. For example, switching from the concentrated 300 units/mL version of insulin glargine requires starting Semglee at about 80% of that dose. Switching from NPH insulin also requires specific adjustments depending on whether you were injecting once or twice daily. In all cases, your doctor will want you to monitor your blood sugar more frequently during the first few weeks after any insulin change, even a simple brand swap, just to confirm everything is tracking as expected.
Cost Differences
Cost is one of the main reasons people end up searching this question. Semglee was specifically positioned as a lower-cost alternative to Lantus. The actual price you pay depends heavily on your insurance plan. Many commercial insurers and Medicare Part D plans have moved Semglee into a preferred formulary position, which can mean lower copays than Lantus. Some plans have dropped Lantus from their formularies entirely, effectively requiring the switch.
Dispensing data from a JAMA Health Forum analysis shows that Semglee adoption surged after favorable formulary changes, particularly in the commercial insurance and mail-order pharmacy channels. In Medicare, Medicaid, and cash-pay settings, uptake has also grown steadily. If your plan covers both, Semglee will generally be the cheaper option, though you should check your specific formulary to confirm.
Storage and Handling
Both Semglee and Lantus follow the same storage rules. Unopened vials and pens should stay refrigerated between 36°F and 46°F (2°C to 8°C) until their printed expiration date. Once you start using a pen or vial, it can be kept at room temperature (up to 86°F or 30°C) for 28 days. After that, discard it even if insulin remains. You should never freeze either product, and both should be kept out of direct heat and sunlight.
The pen devices are slightly different in design, so if you’re switching, take a moment to familiarize yourself with the new pen’s dose dial and injection button. The basic process of priming, dialing your dose, and injecting is the same, but the feel and click pattern may differ.